A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra (JNJ-2113) achieved significantly higher skin clearance at 16 ...

Icotrokinra demonstrated a favorable safety profile, with 50% of adolescents treated with icotrokinra experienced ≥1 adverse event (AE), compared to 73% of adolescents receiving placebo at 16 weeks.

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in ...

Icotrokinra is an investigational oral IL-23 inhibitor peptide. Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).

J&J conducted the ANTHEM-UC trial (NCT06049017) of icotrokinra, an investigational targeted oral peptide that selectively blocks the IL-23 receptor, which reported a clinical response rate of 63.5 ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline ...

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to ...

Icotrokinra is being studied in the pivotal Phase 3 ICONIC clinical development program in moderate-to-severe plaque psoriasis and active psoriatic arthritis and the Phase 2b ANTHEM-UC study in ...